RTS,S is considered the first anti-malaria vaccine candidate. The phase 3 trial for the vaccine involving young African children demonstrated significant efficacy beyond the efficacy observed by the use of conventional preventative measures, proving further benefit in preventing<unk> . On July 24 2014, GSK submitted a regulatory application to the European Medicines Agency (EMA) for approval of the vaccine. If granted, the World Health Organization (WHO) intends to recommend the RTS,S<unk>  vaccine in 2015. Other vaccines are also in the making, but still require further validation of their clinical efficacy.
Malaria future or investigational therapies
Babesiosis primary prevention
Bourbon virus infection secondary prevention
Cardiac diseases in AIDS prevention
Influenza primary prevention
Psittacosis primary prevention
Relapsing fever primary prevention
Listeriosis primary prevention